Vicore Pharma Holding
VICO | ST
Overview
Corporate Details
- ISIN(s):
- SE0007577895 (+1 more)
- LEI:
- 549300KTNBPTZLF01130
- Country:
- Sweden
- Address:
- Postbox 14, 414 51 Göteborg
- Website:
- https://vicorepharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of disease-modifying therapies by targeting the angiotensin II type 2 (AT2) receptor. The company's strategy focuses on activating this receptor to stop and reverse disease pathology, primarily in severe respiratory diseases such as idiopathic pulmonary fibrosis (IPF). Its lead drug candidate is buloxibutid (C21), a first-in-class, orally available small molecule AT2 receptor agonist (ATRAG) in clinical development. In addition to its drug pipeline, Vicore is developing Almee™, a cognitive behavioral therapy-based digital therapeutic designed to address the psychological impact of living with pulmonary fibrosis. Almee™ has received Breakthrough Device Designation from the U.S. FDA. The company utilizes its expertise in ATRAG chemistry and biology to expand its pipeline with new therapies for additional indications.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Vicore Pharma Holding.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-22 08:00 |
Interim Report
|
Swedish | 2.2 MB | |
| 2025-08-22 08:00 |
Interim Report
|
English | 2.2 MB | |
| 2025-06-30 09:00 |
Declaration of Voting Results & Voting Rights Announcements
Increase in number of shares and votes in Vicore Pharma
|
English | 102.5 KB | |
| 2025-06-30 09:00 |
Declaration of Voting Results & Voting Rights Announcements
Ökning av antalet aktier och röster i Vicore Pharma
|
Swedish | 107.6 KB | |
| 2025-05-06 16:25 |
Post-Annual General Meeting Information
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)
|
English | 110.7 KB | |
| 2025-05-06 16:25 |
Post-Annual General Meeting Information
Kommuniké från årsstämma i Vicore Pharma Holding AB (publ)
|
Swedish | 111.7 KB | |
| 2025-05-06 08:00 |
Quarterly Report
|
Swedish | 15.3 MB | |
| 2025-05-06 08:00 |
Interim Report
|
English | 14.5 MB | |
| 2025-03-26 08:30 |
Pre-Annual General Meeting Information
Kallelse till årsstämma i Vicore Pharma Holding AB (publ)
|
Swedish | 152.7 KB | |
| 2025-03-26 08:30 |
Pre-Annual General Meeting Information
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)
|
English | 154.5 KB | |
| 2025-03-26 08:00 |
Annual Report
|
Swedish | 44.4 MB | |
| 2025-03-26 08:00 |
Annual Report
|
English | 43.4 MB | |
| 2025-02-27 08:00 |
Earnings Release
|
Swedish | 6.4 MB | |
| 2025-02-27 08:00 |
Annual Report
|
English | 7.9 MB | |
| 2024-10-31 09:00 |
Share Issue/Capital Change
Ökning av antalet aktier och röster i Vicore Pharma
|
Swedish | 107.9 KB |
Automate Your Workflow. Get a real-time feed of all Vicore Pharma Holding filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Vicore Pharma Holding via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-09-16 | Carl Johan Dalsgaard | Other | Other | 100,000 | N/A |
| 2020-10-06 | Carl Johan Dalsgaard | Other | Other | 100,000 | N/A |
| 2020-06-04 | Heidi Hunter | Other | Buy | 175,000 | N/A |
